Skip to main content

Table 1 The PAH Phenotype in MCT-Injected Rats: Near-Full Prevention by Early Treatment with VIP *

From: VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

Measurements

Control, untreated

MCT +

P value (post hoc)

  

0

VIP

†

**

††

RV systolic pressure (mm Hg)

24.3 ± 2.4

61.4 ± 4.8

29.9 ± 1.8

< 0.05

< 0.05

NS

Arteriolar medial/luminal area

0.76 ± 0.07

3.9 ± 0.51

1.5 ± 0.2

< 0.05

< 0.05

NS

RV/(LV+septum) weight ratio

0.26 ± 0.01

0.56 ± 0.03

0.35 ± 0.01

< 0.05

< 0.05

NS

Lung inflammation (0-4)

0.20 ± 0.17

3.0 ± 0.26

0.3 ± 0.21

< 0.05

< 0.05

NS

  1. * VIP treatment was begun on the same day as MCT. ANOVA: p < 0.0001
  2. † MCT alone vs. control; ** VIP pretreatment vs. MCT alone; †† VIP pretreatment vs. control.